ArticleCulture, medicine and psychiatry2009
Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster.
Article in Culture, medicine and psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Too Big to Lose Weight: How Pharmaceuticalization Corrupts the Right to Health.Health and human rights · 2025Article
- Quantifying Industry Spending on Promotional Events Using Open Payments Data.JAMA health forum · 2024Article
- Promoting opioids, a story about how to influence medical science and opinions.Frontiers in medicine · 2024Article
- What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review.Cochrane evidence synthesis and methods · 2023Review
- How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.BMJ open · 2022Article
- The influence of corporate market power on health: exploring the structure-conduct-performance model from a public health perspective.Globalization and health · 2021Review
- Moving towards less biased research.BMJ open science · 2021Article
- Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation.Journal of bioethical inquiry · 2020Article
- An Illness of Power: Gender and the Social Causes of Depression.Culture, medicine and psychiatry · 2016Review
- "Just Advil": Harm reduction and identity construction in the consumption of over-the-counter medication for chronic pain.Social science & medicine (1982) · 2015Article
- Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.Social science & medicine (1982) · 2015Article
- Deep pharma: psychiatry, anthropology, and pharmaceutical detox.Culture, medicine and psychiatry · 2014Article
- Who has used internal company documents for biomedical and public health research and where did they find them?PloS one · 2014Article
- The most transformative drugs of the past 25 years: a survey of physicians.Nature reviews. Drug discovery · 2013Review
- United States private-sector physicians and pharmaceutical contract research: a qualitative study.PLoS medicine · 2012Article
- The changing face of chronic illness management in primary care: a qualitative study of underlying influences and unintended outcomes.Annals of family medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, I analyze documentary evidence from a pharmaceutical company's strategic marketing campaign to expand the sale of an antipsychotic medication beyond its conventional market. I focus on the role of the managerial function known as channel marketing, the task of which is to minimize friction, achieve coordination and add value in the distribution of the company's products. However, the path to achieving these objectives is challenged because members of the marketing channel, or intermediaries, may not be contractual members of the channel; in fact they may have widely divergent goals or may even be hostile to the manufacturer's efforts at control. This can be construed to be the case for physicians and others who are in the pharmaceutical manufacturer's distribution channel but not of it. Their views and actions must somehow be brought into alignment with the manufacturer's goals. This paper seeks to show part of the process from the manufacturer's strategic standpoint, in which potential dissenters are incorporated into the pharmaceutical company distribution channel. The routinization of this incorporation results in the diminishment of psychiatry's professional autonomy by means of what is-paradoxically to them, but not to a student of marketing-a competitive threat. The paper concludes with a discussion of corporate power.
Indexed as
Identifiers
19247823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.